Date: 2014-01-07
Type of information: Fundraising
Company: Isarna Therapeutics (Germany)
Investors: AT NewTec (Germany), MIG-managed funds (Germany)
Amount: € 13 Million
Funding type: fundraising
Planned used: Proceeds will be used to advance the company\'s pipeline of next generation oligonucleotides that inhibit various isoforms of TGF-β, a key molecular pathway implicated in mechanisms used by cancer cells to evade immune system detection and to aid in tumor proliferation.
Others: * On January 7, 2014, Isarna Therapeutics has announced that it has raised €13 million (USD 17.8 Mio) in equity from new private investor AT NewTec and current investors, MIG-managed funds.
Therapeutic area: Cancer - Oncology
